Vaccine Reduces Tau Tangle Formation, Improves Cognitive Functioning in Alzheimer’s Mouse Model

Vaccine Reduces Tau Tangle Formation, Improves Cognitive Functioning in Alzheimer’s Mouse Model
A vaccine produced using virus-like particles was able to improve cognitive functioning and reduce the accumulation of tau protein aggregates — a hallmark of Alzheimer’s disease — in a mouse model of the disease, a study shows. The study, “Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy,” was published in the journal NPJ Vaccines. The characteristic features of Alzheimer’s disease, such as disrupted communication between nerve cells, are thought to be partly caused by the presence of abnormal protein aggregates — amyloid plaques and tau tangles — in the brain. Previous research has shown that antibodies targeting the hyperphosphorylated form of the tau protein — when the protein becomes heavily tagged with phosphor-molecules promoting its aggregation into tangles — are relatively safe and effective at reducing tau accumulation. Some of these therapies are being tested in clinical trials, such as Genentech’s RO7105705 or AbbVie’s ABBV-8E12. However, there are disadvantages to these kinds of therapies, including high cost and the need for repeated administrations. Researchers at the University of New Mexico now have developed a vaccine that can target tau and may
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *